Which Current and Novel Diagnostic Avenues for Bacterial Respiratory Diseases?

Héloïse Rytter; Anne Jamet; Mathieu Coureuil; Alain Charbit; Elodie Ramond

doi:10.3389/fmicb.2020.616971

Which Current and Novel Diagnostic Avenues for Bacterial Respiratory Diseases?

Front Microbiol. 2020 Dec 10:11:616971. doi: 10.3389/fmicb.2020.616971. eCollection 2020.

Authors

Héloïse Rytter^{1

2

3}, Anne Jamet^{1

2

3

4}, Mathieu Coureuil^{1

2

3}, Alain Charbit^{1

2

3}, Elodie Ramond^{1

2

3}

Affiliations

¹ Université de Paris, Paris, France.
² INSERM U1151, Institut Necker-Enfants Malades. Team 7, Pathogenesis of Systemic Infections, Paris, France.
³ CNRS UMR 8253, Paris, France.
⁴ Department of Clinical Microbiology, Necker Enfants-Malades Hospital, AP-HP, Centre Université de Paris, Paris, France.

Abstract

Bacterial acute pneumonia is responsible for an extremely large burden of death worldwide and diagnosis is paramount in the management of patients. While multidrug-resistant bacteria is one of the biggest health threats in the coming decades, clinicians urgently need access to novel diagnostic technologies. In this review, we will first present the already existing and largely used techniques that allow identifying pathogen-associated pneumonia. Then, we will discuss the latest and most promising technological advances that are based on connected technologies (artificial intelligence-based and Omics-based) or rapid tests, to improve the management of lung infections caused by pathogenic bacteria. We also aim to highlight the mutual benefits of fundamental and clinical studies for a better understanding of lung infections and their more efficient diagnostic management.

Keywords: artificial intelligence; diagnostic test; lung disease (diagnosis); rapid test; respiratory tract infection.

Publication types

Review